CA2416492C - Treatment of glycogen storage disease type ii - Google Patents
Treatment of glycogen storage disease type ii Download PDFInfo
- Publication number
- CA2416492C CA2416492C CA002416492A CA2416492A CA2416492C CA 2416492 C CA2416492 C CA 2416492C CA 002416492 A CA002416492 A CA 002416492A CA 2416492 A CA2416492 A CA 2416492A CA 2416492 C CA2416492 C CA 2416492C
- Authority
- CA
- Canada
- Prior art keywords
- glucosidase
- alpha
- administration
- human acid
- disease type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010053185 Glycogen storage disease type II Diseases 0.000 title claims abstract description 61
- 201000004502 glycogen storage disease II Diseases 0.000 title claims abstract description 60
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title abstract description 26
- 239000002253 acid Substances 0.000 claims abstract description 44
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 14
- 230000003442 weekly effect Effects 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000007345 glycogen storage disease Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 description 36
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 21
- 102000045921 human GAA Human genes 0.000 description 21
- 229920002527 Glycogen Polymers 0.000 description 19
- 229940096919 glycogen Drugs 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 8
- 230000000366 juvenile effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000001964 muscle biopsy Methods 0.000 description 7
- 230000009325 pulmonary function Effects 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- -1 NaCI) Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010011469 Crying Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 229960000520 diphenhydramine Drugs 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008111 motor development Effects 0.000 description 4
- 238000009258 post-therapy Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000007379 Muscle Hypotonia Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 206010016165 failure to thrive Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010069118 Gross motor delay Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21923700P | 2000-07-18 | 2000-07-18 | |
| US60/219,237 | 2000-07-18 | ||
| PCT/US2001/021651 WO2002005841A1 (en) | 2000-07-18 | 2001-07-10 | Treatment of glycogen storage disease type ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2416492A1 CA2416492A1 (en) | 2002-01-24 |
| CA2416492C true CA2416492C (en) | 2008-04-29 |
Family
ID=22818451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002416492A Expired - Lifetime CA2416492C (en) | 2000-07-18 | 2001-07-10 | Treatment of glycogen storage disease type ii |
Country Status (17)
| Country | Link |
|---|---|
| US (10) | US7056712B2 (enExample) |
| EP (4) | EP3108895B1 (enExample) |
| JP (10) | JP5113312B2 (enExample) |
| AT (1) | ATE355075T1 (enExample) |
| AU (3) | AU7194101A (enExample) |
| BR (1) | BR0113006A (enExample) |
| CA (1) | CA2416492C (enExample) |
| CY (2) | CY1120977T1 (enExample) |
| DE (1) | DE60126947T2 (enExample) |
| DK (5) | DK2767291T3 (enExample) |
| ES (5) | ES2700865T3 (enExample) |
| LT (3) | LT3108895T (enExample) |
| MX (1) | MXPA03000474A (enExample) |
| PT (5) | PT1301201E (enExample) |
| SI (3) | SI2767291T1 (enExample) |
| TW (1) | TWI280882B (enExample) |
| WO (1) | WO2002005841A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2767291T3 (en) * | 2000-07-18 | 2016-12-05 | Univ Duke | Treatment of glycogen storage disease type II |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| DE60224816T2 (de) * | 2001-04-30 | 2009-01-22 | ZyStor Therapeutics, Inc., Milwaukee | Subzelluläres targeting von therapeutischen proteinen |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US6981964B2 (en) | 2001-05-22 | 2006-01-03 | Boston Scientific Scimed, Inc. | Draining bodily fluids with a stent |
| US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US6733536B1 (en) | 2002-10-22 | 2004-05-11 | Scimed Life Systems | Male urethral stent device |
| ES2371913T3 (es) * | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7129049B2 (en) * | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
| AU2005212435B2 (en) * | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
| CA2669347A1 (en) * | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| PT2318037E (pt) | 2008-07-08 | 2015-05-20 | Univ Duke | Método de tratamento da doença de armazenamento de glicogénio |
| EP3679942A1 (en) | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| US8809282B2 (en) | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
| WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
| EP3622821A1 (en) | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| CA2961762C (en) | 2014-09-30 | 2024-03-05 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| US11096991B2 (en) | 2015-05-07 | 2021-08-24 | The University Of Tokyo | Nanoreactor using polyion complex polymersomes, and method for producing same |
| EP3344337A4 (en) * | 2015-08-31 | 2019-03-06 | Duke University | METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES |
| US10940125B2 (en) | 2015-09-18 | 2021-03-09 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
| MY198085A (en) | 2015-12-30 | 2023-07-31 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| US10227577B2 (en) | 2016-03-30 | 2019-03-12 | Amicus Therapeutics, Inc. | Method for selection of high M6P recombinant proteins |
| MA44874A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type ii |
| HRP20230576T1 (hr) | 2017-05-15 | 2023-09-01 | Amicus Therapeutics, Inc. | Rekombinantna ljudska kisela alfa-glukozidaza |
| IL273427B2 (en) | 2017-09-22 | 2025-04-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous polycythemia vera type II |
| WO2020163480A1 (en) * | 2019-02-05 | 2020-08-13 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3063911A (en) * | 1961-04-03 | 1962-11-13 | Taisho Pharmaceutical Co Ltd | Acid-stable digestive enzyme preparation and process of making same |
| US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US6118045A (en) * | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| BR9910323A (pt) | 1998-05-13 | 2001-01-30 | Harbor Ucla | Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma |
| EP2020438B1 (en) * | 1998-12-07 | 2018-04-11 | Genzyme Corporation | Treatment of pompe's disease |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| DK2767291T3 (en) | 2000-07-18 | 2016-12-05 | Univ Duke | Treatment of glycogen storage disease type II |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2005212435B2 (en) * | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
-
2001
- 2001-07-10 DK DK14167882.1T patent/DK2767291T3/en active
- 2001-07-10 DK DK18194771.4T patent/DK3449934T3/da active
- 2001-07-10 US US09/902,461 patent/US7056712B2/en not_active Expired - Lifetime
- 2001-07-10 LT LTEP16178390.7T patent/LT3108895T/lt unknown
- 2001-07-10 PT PT01951000T patent/PT1301201E/pt unknown
- 2001-07-10 MX MXPA03000474A patent/MXPA03000474A/es active IP Right Grant
- 2001-07-10 AT AT01951000T patent/ATE355075T1/de active
- 2001-07-10 PT PT181947714T patent/PT3449934T/pt unknown
- 2001-07-10 CA CA002416492A patent/CA2416492C/en not_active Expired - Lifetime
- 2001-07-10 SI SI200131057A patent/SI2767291T1/sl unknown
- 2001-07-10 SI SI200131068T patent/SI3108895T1/sl unknown
- 2001-07-10 ES ES16178390T patent/ES2700865T3/es not_active Expired - Lifetime
- 2001-07-10 DE DE60126947T patent/DE60126947T2/de not_active Expired - Lifetime
- 2001-07-10 LT LTEP14167882.1T patent/LT2767291T/lt unknown
- 2001-07-10 LT LTEP18194771.4T patent/LT3449934T/lt unknown
- 2001-07-10 EP EP16178390.7A patent/EP3108895B1/en not_active Expired - Lifetime
- 2001-07-10 ES ES14167882.1T patent/ES2599401T3/es not_active Expired - Lifetime
- 2001-07-10 JP JP2002511773A patent/JP5113312B2/ja not_active Expired - Lifetime
- 2001-07-10 PT PT141678821T patent/PT2767291T/pt unknown
- 2001-07-10 AU AU7194101A patent/AU7194101A/xx active Pending
- 2001-07-10 ES ES01951000T patent/ES2277931T3/es not_active Expired - Lifetime
- 2001-07-10 AU AU2001271941A patent/AU2001271941B2/en not_active Expired
- 2001-07-10 EP EP18194771.4A patent/EP3449934B1/en not_active Expired - Lifetime
- 2001-07-10 DK DK16178390.7T patent/DK3108895T3/en active
- 2001-07-10 EP EP01951000A patent/EP1301201B1/en not_active Revoked
- 2001-07-10 EP EP14167882.1A patent/EP2767291B1/en not_active Expired - Lifetime
- 2001-07-10 SI SI200131073T patent/SI3449934T1/sl unknown
- 2001-07-10 BR BR0113006-4A patent/BR0113006A/pt not_active Application Discontinuation
- 2001-07-10 TW TW090116828A patent/TWI280882B/zh not_active IP Right Cessation
- 2001-07-10 PT PT16178390T patent/PT3108895T/pt unknown
- 2001-07-10 WO PCT/US2001/021651 patent/WO2002005841A1/en not_active Ceased
- 2001-07-10 PT PT70010913T patent/PT1782825E/pt unknown
- 2001-07-10 DK DK01951000T patent/DK1301201T3/da active
- 2001-07-10 ES ES07001091.3T patent/ES2523024T3/es not_active Expired - Lifetime
- 2001-07-10 ES ES18194771T patent/ES2799882T3/es not_active Expired - Lifetime
- 2001-07-10 DK DK07001091.3T patent/DK1782825T3/da active
-
2005
- 2005-01-20 US US11/039,281 patent/US20050123531A1/en not_active Abandoned
-
2007
- 2007-08-13 US US11/889,457 patent/US20080175833A1/en not_active Abandoned
- 2007-12-03 JP JP2007312804A patent/JP2008081507A/ja active Pending
-
2009
- 2009-10-22 US US12/604,267 patent/US20100254966A1/en not_active Abandoned
-
2010
- 2010-02-10 AU AU2010200487A patent/AU2010200487A1/en not_active Ceased
-
2011
- 2011-03-30 US US13/064,556 patent/US20120058132A1/en not_active Abandoned
- 2011-08-09 JP JP2011173569A patent/JP2012006953A/ja active Pending
-
2012
- 2012-08-23 US US13/593,148 patent/US8900552B2/en not_active Expired - Fee Related
-
2013
- 2013-08-05 JP JP2013162201A patent/JP5792774B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-09 JP JP2014141336A patent/JP2014185187A/ja active Pending
- 2014-09-12 US US14/485,071 patent/US9370556B2/en not_active Expired - Fee Related
-
2016
- 2016-01-14 JP JP2016005132A patent/JP6163216B2/ja not_active Expired - Lifetime
- 2016-03-10 US US15/066,211 patent/US9907839B2/en not_active Expired - Fee Related
-
2017
- 2017-05-19 JP JP2017099515A patent/JP2017137357A/ja active Pending
- 2017-10-17 JP JP2017201250A patent/JP2018002749A/ja active Pending
-
2018
- 2018-01-19 US US15/876,086 patent/US10792341B2/en not_active Expired - Fee Related
- 2018-09-13 JP JP2018171154A patent/JP2018199721A/ja active Pending
- 2018-12-07 CY CY181101308T patent/CY1120977T1/el unknown
-
2019
- 2019-11-08 JP JP2019202851A patent/JP2020019822A/ja active Pending
-
2020
- 2020-06-24 CY CY20201100587T patent/CY1123084T1/el unknown
- 2020-07-27 US US16/940,054 patent/US20210169996A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2416492C (en) | Treatment of glycogen storage disease type ii | |
| AU2001271941A1 (en) | Treatment of glycogen storage disease type II | |
| AU2018247261B2 (en) | Treatment of glycogen storage disease type II | |
| EP1782825B1 (en) | Treatment of glycogen storage diseases type II | |
| HK40005572B (en) | Treatment of glycogen storage disease type ii | |
| HK40005572A (en) | Treatment of glycogen storage disease type ii | |
| AU2015202140A1 (en) | Treatment of glycogen storage disease type II | |
| AU2012216860A1 (en) | Treatment of glycogen storage disease type II | |
| HK1054690B (en) | Treatment of glycogen storage disease type ii | |
| AU2007202469A1 (en) | Treatment of glycogen storage disease type II | |
| HK1230103A1 (en) | Treatment of glycogen storage disease type ii | |
| HK1197656B (en) | Treatment of glycogen storage disease type ii | |
| HK1230103B (en) | Treatment of glycogen storage disease type ii | |
| HK1103363B (en) | Treatment of glycogen storage diseases type ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210712 |